Drug Information Related to Levocetirizine Dihydrochloride
01. Sepracor Announces Third Quarter 2006 Operating Results. - Free Online...
MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) today announced
its consolidated financial results for the third quarter of 2006. For
the three months ended September 30, 2006, Sepracor's consolidated
revenues were $289.3 million, of which revenues from pharmace...
02. New prescription allergy treatment XYZAL(R) (levocetirizine ...
Brussels, Belgium and Paris, France, October 2, 2007 - 8:00 am CET -
UCB and sanofi-aventis announced today that XYZAL®, a new once-daily
medication used to treat indoor and outdoor allergies, as well as
chronic idiopathic urticaria, is now available by pr...
03. Chronic urticaria: clinical aspects and focus on a new antihistamine ....
Abstract
...
04. FDA Approves XYZAL(R) Tablets for the Treatment of Seasonal and Year ....
UCB and sanofi-aventis
announced today that the U.S. Food and Drug
Administration (FDA) has approved XYZAL®
(levocetirizine
dihydrochloride), a new once-daily prescription antihistamine
that
delivers a rapid and long-lasting effect for the relief of
s...